EDEN PRAIRIE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving ...
4don MSN
NeuroOne targets at least $10.5M revenue in 2026 while advancing brain and pain therapy platforms
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Management View Dave Rosa, President, CEO & Director, stated the company is projecting fiscal year 2026 sales to be "at least $10.5 million, ...
Ablation System Product Launch in 2024 were Performed in Fiscal Q1 2026, Showing Growing Adoption Following FDA 510(k) Clearance, Successfully Completed Nine Trigeminal Neuralgia Cases to Date, with ...
CLEVELAND – Trigeminal neuralgia (TN) is a debilitating, chronic syndrome that causes sudden, severe, electric shock-like pain in the face. While TN isn’t life-threatening, it can severely alter ...
NeuroOne Medical Technologies Corporation announced that CEO Dave Rosa participated in an interview on Today’s Marketplace, discussing advancements in epilepsy treatment alongside Dr. Jessica Clark ...
Company on track to submit OneRF 510(k) application to the FDA in the second quarter of calendar year 2023 EDEN PRAIRIE, Minn., Dec. 6, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation ...
EDEN PRAIRIE, Minn., June 25, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving ...
NeuroOne Medical Technologies Corporation NMTC recently received FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System, a minimally invasive solution for treating severe facial pain. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results